InvestorsHub Logo
Followers 5
Posts 356
Boards Moderated 0
Alias Born 03/18/2013

Re: Aumeoli post# 184652

Saturday, 03/30/2019 2:22:05 PM

Saturday, March 30, 2019 2:22:05 PM

Post# of 423945
I agree with your last two posts. If Amarin has a high volume low price approach which seems to be the case then it will be difficult for generics to undercut them significantly in price.

Michael Yee/Jefferies has opined that most other analysts are not taking into account the still substantial revenue stream after patent expansion. Any potential acquirer is probably taking this into account.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News